<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05101005</url>
  </required_header>
  <id_info>
    <org_study_id>SJDCB-01</org_study_id>
    <nct_id>NCT05101005</nct_id>
  </id_info>
  <brief_title>Long-term Efficacy of Drug-coated Balloon Versus Drug-eluting Stent in Large de Novo Coronary Lesions</brief_title>
  <official_title>A Prospective, Multi-center, Randomized Trial Comparing the Long-term Efficacy of Drug-coated Balloon Versus Drug-eluting Stent in Large de Novo Coronary Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lepu Medical Technology (Beijing) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lepu Medical Technology (Beijing) Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of drug-coated balloon versus drug-eluting stent for the treatment&#xD;
      of large de novo coronary lesions(RVD=2.75~4.0mm).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients were randomly assigned (1:1) to receive angioplasty with DCB or implantation of a&#xD;
      DES. Dual anti-platelet therapy was given according to current guidelines. Follow-up was&#xD;
      originally scheduled at by telephone or clinical visit at 1 month, 6 months, and 12 months&#xD;
      after discharge. The primary endpoint is a composite endpoint of cardiac death, target vessel&#xD;
      related myocardial infarction, and target lesion revascularization (TLF) at 12 months follow&#xD;
      up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target lesion failure</measure>
    <time_frame>12 months follow-up</time_frame>
    <description>A composite endpoint consisting of cardiac death, target vessel-related myocardial infarction, and target lesion revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>During the hospital stay, up to 7 days after PCI</time_frame>
    <description>Consisting of device success ( after successful delivery of the study balloon, the visual residual stenosis of the target lesion is less than 50%, TIMI level 3 blood flow ) , Lesion success (defined as the proportion of the target lesions in which the final stenosis is &lt;20% after treatment with any other adjunctive therapy ) , Clinical success ( Defined as no major adverse cardiac events caused by ischemia during the subject's hospitalization).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure</measure>
    <time_frame>1 month, 6months follow-up</time_frame>
    <description>A composite endpoint consisting of cardiac death, target vessel-related myocardial infarction, and target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-oriented composite endpoint</measure>
    <time_frame>1 month, 6months,12 months follow-up</time_frame>
    <description>A composite of all-cause mortality, myocardial infarction, and any revascularization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Drug-coated Balloon</condition>
  <arm_group>
    <arm_group_label>Drug-coated balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug-coated balloon is used to treat coronary artery stenosis lesions and improve myocardial blood flow.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sirolimus-Eluting Stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sirolimus-Eluting Stent is treated for coronary artery stenosis lesions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug-Coated Balloon</intervention_name>
    <description>Drug-coated balloon is a fast-exchange balloon dilatation catheter, used to treat coronary artery stenosis lesions.</description>
    <arm_group_label>Drug-coated balloon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sirolimus-Eluting Stent</intervention_name>
    <description>Sirolimus-Eluting Stent is treated for coronary artery stenosis lesions.</description>
    <arm_group_label>Sirolimus-Eluting Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years and ≤80 years, regardless of gender;&#xD;
&#xD;
          2. De novo lesion in a native coronary artery;&#xD;
&#xD;
          3. Stable angina, or unstable angina, or old myocardial infarction or asymptomatic&#xD;
             myocardial ischemia;&#xD;
&#xD;
          4. Reference vessel diameter is 2.75mm-4.0mm with diameter stenosis ≥70% or ≥50% (with&#xD;
             evidence of ischemia) and TIMI flow ≥1;&#xD;
&#xD;
          5. The subject can receive any type of coronary vascular revascularization (including&#xD;
             balloon angioplasty, stent implantation or coronary artery bypass grafting);&#xD;
&#xD;
          6. The subject who can understand the purpose of the trial, voluntarily participate in&#xD;
             and sign an informed consent form, and is willing to accept clinical follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Reference vessel diameter &lt;2.75 mm or &gt;4.0 mm;&#xD;
&#xD;
          2. In stent restenosis;&#xD;
&#xD;
          3. Left main lesion, chronic complete occlusion lesion;&#xD;
&#xD;
          4. Ostial lesion ≤2mm from the LM, or bifurcation lesion with branch vessel&#xD;
             diameter≥2.5mm;&#xD;
&#xD;
          5. There is a large scale of thrombus in the target vessel, and the thrombus grade &gt;3&#xD;
             after thrombolysis or aspiration;&#xD;
&#xD;
          6. Severe heart failure (NYHA IV);&#xD;
&#xD;
          7. Severe renal failure (GFR&lt;30ml/min) or undergoing hemodialysis treatment;&#xD;
&#xD;
          8. Severe liver failure (bilirubin is over 2 times the upper limit of normal, or alanine&#xD;
             aminotransferase is over 3 times the upper limit of normal);&#xD;
&#xD;
          9. Patients with vein graft restenosis after bypass or severe heart valve disease;&#xD;
&#xD;
         10. Pregnant or breastfeeding female patients;&#xD;
&#xD;
         11. The life expectancy of the patient is less than 12 months;&#xD;
&#xD;
         12. The subject cannot be treated with anticoagulation because of bleeding tendency,&#xD;
             history of active peptic ulcer, stroke in the 6 months before surgery, anti-platelet&#xD;
             agents or anticoagulant treatment contraindications;&#xD;
&#xD;
         13. Anemia (women's hemoglobin &lt;117g/L, or men's hemoglobin &lt;134g/L), or thrombocytopenia&#xD;
             detected before the intervention within 6 months (&lt;100×10⁹/L);&#xD;
&#xD;
         14. Planned to perform non-cardiac surgery within 12 months after index procedure;&#xD;
&#xD;
         15. The subject who participated in other clinical trials of drugs or instruments and did&#xD;
             not reach time of primary endpoint;&#xD;
&#xD;
         16. Heart transplant patients;&#xD;
&#xD;
         17. Allergic to aspirin, clopidogrel, heparin, contrast agents, or paclitaxel;&#xD;
&#xD;
         18. The investigator judged that the patient had poor compliance and could not complete&#xD;
             the study as required.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yansong Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Songjiang Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yansong Li</last_name>
    <phone>8618221277176</phone>
    <email>liyansong021@126.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 13, 2021</study_first_submitted>
  <study_first_submitted_qc>October 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

